Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mutiple myeloma

- PMLiVE

Pfizer and Astellas’ Xtandi approved by FDA for earlier prostate cancer indication

Xtandi is the first androgen receptor signalling inhibitor approved for this patient population

- PMLiVE

New genetic variants linked to prostate cancer in men with African ancestry

A dataset was compiled for the research containing DNA from over 944,000 men

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

Janssen reveals positive results for nipocalimab in rheumatoid arthritis

About 13 million people worldwide are affected by the chronic inflammatory disease

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Scientists discover way to reverse drug resistance in prostate cancer

Targeting ‘hijacked’ white blood cells could reverse drug resistance and slow tumour progression

- PMLiVE

International study reveals 11 new genes linked to aggressive prostate cancer

Findings from the study could improve treatment options for patients with prostate cancer

- PMLiVE

Bristol Myers Squibb reveals plans to double number of drugs in registrational trials

The drugmaker expects to expand its research pipeline from six to 12 over next 18 months

- PMLiVE

ICR study supports use of new radioactive treatment for advanced prostate cancer

Experts are calling for NICE to assess if the treatment should be made available on the NHS

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Pfizer and Astellas’ Xtandi granted FDA priority review for new prostate cancer indication

The treatment is already approved in the US for three disease states of prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links